NFE2L2 and breast carcinoma: Xie et al. studied a series of novel direct Keap1-Nrf2 PPI inhibitors and their role in increasing the availability of Nrf2 for antioxidant activity and attenuating estrogen-mediated responses in breast cancer [283].